PD-L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy
| Autor: | Zhen Wang, Wei Zhou, Marisa Dolled-Filhart, Lars Bastholt, Kenneth Emancipator, P. Switten Nielsen, Y. Feng, Torben Steiniche, A. Vestergaard Danielsen, Michael Busch-Sørensen, Henrik Schmidt, Inge Marie Svane, Russell Weiner |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
0301 basic medicine Oncology B7-H1 Antigen/analysis medicine.medical_specialty Letter Skin Neoplasms medicine.medical_treatment Ipilimumab Dermatology Pembrolizumab B7-H1 Antigen 03 medical and health sciences 0302 clinical medicine Melanoma/chemistry Internal medicine medicine Humans Melanoma Chemotherapy business.industry Immunotherapy Middle Aged medicine.disease Surgery Survival Rate 030104 developmental biology Infectious Diseases Skin Neoplasms/chemistry 030220 oncology & carcinogenesis Immunohistochemistry Female Pd l1 expression Nivolumab business medicine.drug |
| Zdroj: | Steiniche, T, Vestergaard Danielsen, A, Wang, Z, Feng, Y, Switten Nielsen, P, Bastholt, L, Schmidt, H, Svane, I M, Dolled-Filhart, M, Emancipator, K, Weiner, R, Busch-Sørensen, M & Zhou, W 2017, ' PD-L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy ', Journal of the European Academy of Dermatology and Venereology, vol. 31, no. 7, pp. e319–e321 . https://doi.org/10.1111/jdv.14106 Steiniche, T, Vestergaard Danielsen, A, Wang, Z, Feng, Y, Switten Nielsen, P, Bastholt, L, Schmidt, H, Svane, I M, Dolled-Filhart, M, Emancipator, K, Weiner, R, Busch-Sørensen, M & Zhou, W 2017, ' PD-L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy ', Journal of the European Academy of Dermatology and Venereology. Supplement, vol. 31, no. 7, pp. e319-e321 . https://doi.org/10.1111/jdv.14106 |
| ISSN: | 0926-9959 2001-2012 |
| Popis: | The association between programmed death ligand 1 (PD-L1) expression and survival among melanoma patients treated with chemotherapy is unclear.1-5 We retrospectively characterized PD-L1 levels in patients with melanoma treated at Aarhus University Hospital in Denmark (2001-2012) using a prototype immunohistochemistry assay (QualTek Molecular Laboratories, Goleta, California, USA) and investigated the association between PD-L1 and overall survival (OS) in patients who received chemotherapy or immunotherapy (interleukin-2, interferon, ipilimumab). None of the patients received pembrolizumab or nivolumab. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text